TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.
Jie Yu(KU Leuven), Jonathan Zalevsky(Nektar Therapeutics (United States)), Mengkun Zhang(Millennium Engineering and Integration (United States)), Jessica Huck Sappal(Takeda (United States)), Karuppiah Kannan(Takeda (United States))
Cited by 0
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
Carbon-dot-supported atomically dispersed gold as a mitochondrial oxidative stress amplifier for cancer treatment
|Nature Nanotechnology|2019|598
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403